Answers are grounded in this paper and cite their sources.
Retrospective analysis shows nusinersen improves motor function in pediatric spinal muscular atrophy, suggesting early treatment benefits.
• Disease-modifying treatments in SMA are documented to change the natural history of SMA. • Evaluation of real-life outcomes in SMA highlights the need for standardized and validated assessments to capture cognitive and multisystemic involvement. • Multidimensional burden of SMA requires adherence to standards of care principles. Disease-modifying treatments in SMA are documented to change the natural history of SMA. Evaluation of real-life outcomes in SMA highlights the need for standardized and validated assessments to capture cognitive and multisystemic involvement. Multidimensional burden of SMA requires adherence to standards of care principles. To evaluate long-term outcome (motor function, ventilation, nutrition, scoliosis, neurophysiological assessments) of pediatric SMA patients treated with nusinersen. 46 patients (19 girls, 27 boys) [SMA type 1 (n= 18), type 2 (n= 15), type 3 (n= 13)] are included to this retrospective study. Median baseline age of SMA type 1, 2 and 3 patients were 6.5 (1.0-123.0); 112.0 (50.0-178.0); 88.0 (31.0-190.0) months; median duration of treatment for type 1, 2 and 3 was 15.2 (6.1-47.4), 38.0 (9.0-44.8), 41.8 (6.6-44.7) months, respectively. Median baseline CHOP-INTEND score was 23.0 (0.0-38.0) points for type 1. Median baseline HMFSE score for type 2 and 3 was 4.0 (1.0-26.0), and 41.0 (17.0-62.0) points, respectively. At last assessment; 3 type 1 patients were able to walk with support; 3 patients with type 3 lost ability of independent walking; median CHOP-INTEND score was 41.0 (3.0-64.0) points for type 1, median HMFSE score was 8.0 (4.0-30.0) points for type 2, and 48.0 (28.0-64.0) points for type 3. There was an overall significant negative correlation between the age of onset of treatment and motor score in all SMA types ( p <0.001). Respiratory (n= 12) and feeding (n= 5) support, scoliosis (n= 33), cognitive involvement/language delay (n= 6), autistic features (n= 2), epilepsy (n= 2) were additional features. This cohort represents a heterogeneous symptomatic SMA population treated with nusinersen. This real-life data echoes that early initiation of treatment positively affects outcome with gains in motor function and/or stabilization, and highlights emerging cognitive involvement. There is a mismatch in outcome parameters, and multidisciplinary care plays an ever-important role in the era of disease-modifying treatments.
No takes yet. Share an insight, caveat, or question.
Yıldız et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: